BACKGROUND: Poor muscle size and function (sarcopenia) have an important role in the age-associated disability process. However, no commonly accepted index of sarcopenia exists for use in epidemiological studies. METHODS: A cohort of 998 community-dwelling African Americans 49-65 years' old at baseline was used to construct the short portable sarcopenia measure (SPSM). SPSM was conceptualized as a measure of sarcopenia that combines estimates of muscle quantity and function into a single scale, is based on component items that can be obtained easily in the field, represents muscle status at a single time point that can be used without sex-specific adjustments, and can be used to follow change in muscle status over time with each person as his or her own control. We used exploratory factor analysis (EFA) to identify a unidimensional scale based on timed chair rises, lean mass, and grip strength divided by height. We used these three items and their EFA factor weights to construct SPSM (mean 9.0, median 9, range 0 [worst] to 18 [best] at baseline). Construct validity of the new measure, over a period of 36 months was examined. RESULTS: SPSM required 8.5 pounds of equipment and 12.4 minutes to complete. It showed good score distribution and convergent, discriminant, and predictive validity with measures of muscle function, body composition, physical performance, psychological factors, and functional limitation cross-sectionally and with muscle function and body composition longitudinally. Extensive sensitivity analyses confirmed SPSM's robustness. CONCLUSIONS: SPSM is a brief, portable, and valid measure of sarcopenia for use in epidemiological research. Similar studies in other populations are needed.
BACKGROUND: Poor muscle size and function (sarcopenia) have an important role in the age-associated disability process. However, no commonly accepted index of sarcopenia exists for use in epidemiological studies. METHODS: A cohort of 998 community-dwelling African Americans 49-65 years' old at baseline was used to construct the short portable sarcopenia measure (SPSM). SPSM was conceptualized as a measure of sarcopenia that combines estimates of muscle quantity and function into a single scale, is based on component items that can be obtained easily in the field, represents muscle status at a single time point that can be used without sex-specific adjustments, and can be used to follow change in muscle status over time with each person as his or her own control. We used exploratory factor analysis (EFA) to identify a unidimensional scale based on timed chair rises, lean mass, and grip strength divided by height. We used these three items and their EFA factor weights to construct SPSM (mean 9.0, median 9, range 0 [worst] to 18 [best] at baseline). Construct validity of the new measure, over a period of 36 months was examined. RESULTS: SPSM required 8.5 pounds of equipment and 12.4 minutes to complete. It showed good score distribution and convergent, discriminant, and predictive validity with measures of muscle function, body composition, physical performance, psychological factors, and functional limitation cross-sectionally and with muscle function and body composition longitudinally. Extensive sensitivity analyses confirmed SPSM's robustness. CONCLUSIONS: SPSM is a brief, portable, and valid measure of sarcopenia for use in epidemiological research. Similar studies in other populations are needed.
Authors: A B Newman; J S Gottdiener; M A Mcburnie; C H Hirsch; W J Kop; R Tracy; J D Walston; L P Fried Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: B H Goodpaster; C L Carlson; M Visser; D E Kelley; A Scherzinger; T B Harris; E Stamm; A B Newman Journal: J Appl Physiol (1985) Date: 2001-06
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Henrik Frederiksen; Jacob Hjelmborg; Jakob Mortensen; Matt McGue; James W Vaupel; Kaare Christensen Journal: Ann Epidemiol Date: 2006-01-10 Impact factor: 3.797
Authors: Douglas K Miller; Fredric D Wolinsky; Elena M Andresen; Theodore K Malmstrom; J Philip Miller Journal: J Gerontol A Biol Sci Med Sci Date: 2008-05 Impact factor: 6.053
Authors: John E Morley; Josep M Argiles; William J Evans; Shalender Bhasin; David Cella; Nicolaas E P Deutz; Wolfram Doehner; Ken C H Fearon; Luigi Ferrucci; Marc K Hellerstein; Kamyar Kalantar-Zadeh; Herbert Lochs; Neil MacDonald; Kathleen Mulligan; Maurizio Muscaritoli; Piotr Ponikowski; Mary Ellen Posthauer; Filippo Rossi Fanelli; Morrie Schambelan; Annemie M W J Schols; Michael W Schuster; Stefan D Anker Journal: J Am Med Dir Assoc Date: 2010-07 Impact factor: 4.669
Authors: Brittany L Bernard; Lauren E Bracey; Kathleen A Lane; Denisha Y Ferguson; Michael A LaMantia; Sujuan Gao; Douglas K Miller; Christopher M Callahan Journal: Alzheimer Dis Assoc Disord Date: 2016 Apr-Jun Impact factor: 2.703
Authors: Douglas K Miller; Theodore K Malmstrom; J Philip Miller; Elena M Andresen; Mario Schootman; Fredric D Wolinsky Journal: J Aging Health Date: 2010-01-05
Authors: Christopher M Callahan; Malaz A Boustani; Arlene A Schmid; Michael A LaMantia; Mary G Austrom; Douglas K Miller; Sujuan Gao; Denisha Y Ferguson; Kathleen A Lane; Hugh C Hendrie Journal: Ann Intern Med Date: 2016-11-22 Impact factor: 25.391
Authors: Christopher M Callahan; Malaz A Boustani; Arlene A Schmid; Mary G Austrom; Douglas K Miller; Sujuan Gao; Carrie S Morris; Mickey Vogel; Hugh C Hendrie Journal: Trials Date: 2012-06-27 Impact factor: 2.279
Authors: Theodore K Malmstrom; Douglas K Miller; Margaret M Herning; John E Morley Journal: J Cachexia Sarcopenia Muscle Date: 2013-03-27 Impact factor: 12.910